Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma

International Journal of Urology, 05/16/2012

Implementation of therapy management measures contributes towards maximizing treatment outcomes with targeted agents in patients with metastatic renal cell carcinoma.

  • Targeted agents have significantly improved outcomes in patients with metastatic renal cell carcinoma, and are changing long–term expectations in these patients.
  • Experience with these agents highlights a distinct safety and tolerability profile, differing from that observed with conventional chemotherapy and radiotherapy.
  • Cardiovascular adverse events have been observed when treating with targeted agents.
  • This is of particular importance for patients with metastatic renal cell carcinoma who are elderly and present with significant comorbidities.
  • A multidisciplinary approach and close collaboration between oncologists and cardiologists is essential for optimal management of cardiovascular adverse events.
  • Strategies for the management of these adverse events include assessment of cardiovascular status at baseline and at regular intervals, patient education, and the use of supportive medication.
  • Effective therapy management allows patients with cardiovascular adverse events to receive and continue targeted therapy with careful monitoring.

Print Article Summary Cat 2 CME Report